Live
- Govt allows export of 99,150 tonnes of onion to 6 countries
- KTR accuses Telangana CM of cheating people in phases
- IPL 2024: Samson elects to field as high-flying Rajasthan Royals take on Lucknow Super Giants
- Manikanta Gautam awarded honorary doctorate
- Shehzad Poonawala calls Arvind Kejriwal 'Pablo Escobar' who runs gang from jail
- Mehbooba Mufti tells voters she believes in uniting, not dividing people
- Elnaaz Norouzi opens up on playing dual roles in 'Ranneeti: Balakot and Beyond'
- Father of youth who died during weight loss surgery urges TN Health Minister to speed up probe
- RSP leader writes to Calcutta HC Chief Justice seeking action against Abhishek Banerjee for 'anti-judiciary' remarks
- BJP, Akali Dal, Congress leaders join AAP in Punjab
Gland Pharma gets USFDA nod for generic injectable
Gland Pharma on Wednesday said it has received approval from the US health regulator to market a generic product used to raise blood pressure.
New Delhi: Gland Pharma on Wednesday said it has received approval from the US health regulator to market a generic product used to raise blood pressurblood pressurblood pressurblood pressure.
The Hyderabad-based company has received tentative approval from the US Food and Drug Administration (USFDA) for Angiotensin II Injection, 2.5 mg/mL Single Dose Vial, it said in a regulatory filing. The company believes that it is the only company with first to file for this product and may be eligible for 180 days of generic drug exclusivity, it added.
Gland Pharma will launch the product with its marketing partner on receipt of final approval, it said. According to IQVIA data, Angiotensin II Injection (2.5 mg/mL Single Dose Vial) has US sales of around USD 38 million for twelve months ended in September 2023. Shares of drug firm were trading 0.68 per cent down at Rs 1,613.35 apiece on the BSE.
